| __timestamp | Axsome Therapeutics, Inc. | Perrigo Company plc |
|---|---|---|
| Wednesday, January 1, 2014 | 1392830 | 675200000 |
| Thursday, January 1, 2015 | 2419289 | 771800000 |
| Friday, January 1, 2016 | 6343648 | 1205500000 |
| Sunday, January 1, 2017 | 7206691 | 1146500000 |
| Monday, January 1, 2018 | 9351522 | 1125800000 |
| Tuesday, January 1, 2019 | 13598030 | 1166100000 |
| Wednesday, January 1, 2020 | 28896749 | 1175500000 |
| Friday, January 1, 2021 | 66646205 | 1111400000 |
| Saturday, January 1, 2022 | 159253661 | 1210100000 |
| Sunday, January 1, 2023 | 323123000 | 1274600000 |
| Monday, January 1, 2024 | 411359000 |
Cracking the code
In the competitive landscape of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. From 2014 to 2023, Axsome Therapeutics, Inc. and Perrigo Company plc have shown contrasting approaches. Axsome's SG&A expenses surged from a modest $1.4 million in 2014 to a staggering $323 million in 2023, reflecting a growth of over 23,000%. This rapid increase highlights their aggressive expansion strategy. In contrast, Perrigo's expenses grew by only 89% over the same period, from $675 million to $1.27 billion, indicating a more stable and controlled cost management approach. While Axsome's strategy might suggest rapid growth and investment in market penetration, Perrigo's steady increase could imply a focus on efficiency and sustainable growth. Understanding these trends offers valuable insights into each company's operational priorities and financial health.
Comparing SG&A Expenses: Merck & Co., Inc. vs Perrigo Company plc Trends and Insights
Selling, General, and Administrative Costs: Pfizer Inc. vs Axsome Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Amgen Inc. and Perrigo Company plc
Operational Costs Compared: SG&A Analysis of Genmab A/S and Axsome Therapeutics, Inc.
Who Optimizes SG&A Costs Better? Catalent, Inc. or Perrigo Company plc
Operational Costs Compared: SG&A Analysis of Walgreens Boots Alliance, Inc. and Perrigo Company plc
Who Optimizes SG&A Costs Better? Halozyme Therapeutics, Inc. or Perrigo Company plc
Cost Management Insights: SG&A Expenses for Lantheus Holdings, Inc. and Perrigo Company plc
SG&A Efficiency Analysis: Comparing Cytokinetics, Incorporated and Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc. and Xenon Pharmaceuticals Inc.: SG&A Spending Patterns Compared
Axsome Therapeutics, Inc. and Catalyst Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing Axsome Therapeutics, Inc. and MannKind Corporation